An interventional study of erector spinae block and paravertebral block anesthesia in Lung Diseases and Pain, Acute, sponsored by South Egypt Cancer Institute. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by South Egypt Cancer Institute · Not applicable, Interventional, and Prevention
Among 13 studies in Lung Diseases with a site in Egypt — 2 open to participants now, 2 under way, 1 of them phase 3. Lung Diseases · Egypt.
Among the 13 studies in Lung Diseases with a site in Egypt, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 with no phase, and was the 9th registered.
1,158 studies on the registry are indexed under Lung Diseases; 182 are open to participants now.
Browse Lung Diseases studies →2 of the 13 studies in Lung Diseases with a site in Egypt are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Egypt, United States, Argentina and 36 more countries
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 140 Lung Diseases studies recruiting now, 76 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 16 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 90 is above the median of 70 across 663 interventional studies indexed under Lung Diseases.
Median enrollment 60 across the 10 interventional studies, 46 across the 3 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 10 most frequent:
South Egypt Cancer Institute is the lead sponsor of 35 studies on the registry; 7 are open to participants now.
South Egypt Cancer Institute has 1 study filed under Lung Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Lung Diseases with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Among the 13 studies in Lung Diseases with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Thoracotomy operations are known to be painful surgical procedures, so providing effective intraoperative and postoperative analgesia is so important for all anaesthesiologists. Ineffective pain management interferes with deep breathing, coughing, and remobilization resulting in atelectasis and pneumonia.
Ultrasound-guided ESP block is a myofascial plane block that provides analgesia for thoracic or abdominal segmental innervation depending on the level of the injection site. Thoracic epidural analgesia (TEA) is considered the gold standard analgesic technique for thoracic surgeries. But the invasiveness of this technique, the rare but serious neurologic complications and the failure rates up to 30% are the disadvantages of epidural analgesia
The aim of this study is to compare the effect of different blocks as TEA, erector spinae block or paravertebral block on improving peri-operative analgesia and post-operative outcome in pulmonary resection in adult patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
insertion of Thoracic epidural anesthesia plus GA with lung isolation using suitable size double lumen tube at level T6
Procedure: Thoracic epidural anesthesia
U/S guided erector spinae block anesthesia using 15 ml local anesthesia plus GA with lung isolation using a suitable size double-lumen tube
Procedure: erector spinae block
U/S guided paravertebral block anesthesia using 15 ml local anesthesia as total volume plus GA with lung isolation using suitable size double lumen tube
Procedure: paravertebral block anesthesia
Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
peri-operative analgesia
Visual Analogue score (resting and during cough) from 0 (no pain) to 10 (worst pain pain measurement
Time frame: up to 48 hours postoperative
Started Jan 2022 (actual). Primary completion is estimated for Jun 2023, 17 months after the start.
Of 184 non-industry interventional studies with no phase under Lung Diseases, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 17 months is below that.
Counting every sponsor, half of 207 studies reached it within 22 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
South Egypt Cancer Institute